Pmda - Pharmaceuticals and Medical Devices Agency

Jump to body

Navigation of each product type

Our recommended contents

Navigation of each product type

Our recommended contents

Here begins the text.

Post-marketing Safety Measures

Click here for detail

Scientific Research and Analyses

Information Services

Regulatory Information

What's newBack number

　　All

June 26, 2020PMDA Risk Communication: Sodium amidotrizoate /amidotrizoate meglumine, etc. posted
June 25, 2020Revisions of PRECAUTIONS:Oxytocin, etc. posted

Pmda - Pharmaceuticals and Medical Devices Agency

JCN 3010005007409

Shin-Kasumigaseki Building, 3-3-2 Kasumigaseki,
Chiyoda-ku, Tokyo 100-0013 Japan

Copyright (C) Pharmaceuticals and Medical Devices Agency, All Rights Reserved.